Versigent (NYSE:VGNT – Get Free Report) Director Kevin Clark sold 48,592 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $48.02, for a total transaction of $2,333,387.84. Following the completion of the sale, the director directly owned 198,979 shares in the company, valued at approximately $9,554,971.58. This represents a 19.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Versigent Price Performance
Shares of Versigent stock traded up $0.71 during trading on Thursday, hitting $46.45. 470,596 shares of the stock were exchanged, compared to its average volume of 1,777,686. The company has a market cap of $3.29 billion and a PE ratio of 24.19. The business’s 50-day simple moving average is $44.16. Versigent has a 12-month low of $26.34 and a 12-month high of $50.88. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 7.29.
Versigent (NYSE:VGNT – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.58 by $0.34. The business had revenue of $2.44 billion during the quarter, compared to analysts’ expectations of $2.29 billion. As a group, research analysts forecast that Versigent will post 7.23 earnings per share for the current year.
Versigent Dividend Announcement
Institutional Trading of Versigent
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new stake in shares of Versigent in the 2nd quarter valued at about $57,000. Sequoia Financial Advisors LLC purchased a new position in Versigent during the 2nd quarter worth approximately $220,000. Kintegral Advisory LLC acquired a new position in Versigent during the second quarter worth approximately $224,000. Engineers Gate Manager LP acquired a new position in Versigent during the second quarter worth approximately $418,000. Finally, Corient Private Wealth LP purchased a new stake in Versigent in the second quarter valued at approximately $426,000.
Wall Street Analyst Weigh In
VGNT has been the topic of several research analyst reports. Royal Bank Of Canada raised Versigent from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $41.00 to $52.00 in a research report on Wednesday, August 5th. Oppenheimer set a $50.00 price target on shares of Versigent in a research note on Tuesday, July 21st. Fox Advisors cut shares of Versigent from an “overweight” rating to an “equal weight” rating in a report on Wednesday, August 5th. Wells Fargo & Company boosted their price objective on shares of Versigent from $48.00 to $56.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, UBS Group lowered their target price on shares of Versigent from $58.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, July 9th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.
Read Our Latest Research Report on VGNT
Versigent Company Profile
Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.
See Also
- Five stocks we like better than Versigent
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
